Tumor antigen gene-modified dendritic cells (DC) generates robust antigen-specific protective antitumor responses. Though the role of CD4 positive and CD8 positive cells in the immunological response to gene-modified DC has been well-characterized, the role of NK cells in this response has been somewhat less clear. Owing to the significant contribution of innate immunity in other model systems, we postulated that NK cells would hold a critical position in the generation of an immune response following immunization with tumor antigen-engineered DC. Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. These responses were dependent on the presence of functional NK cells, although NK cells alone were not sufficient in generating protective responses. Adoptive transfer of NK cells into an NK-deficient but T-cell-competent environment restored the protective response to gene-modified DC immunization. In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4 þ and CD8 þ T cells and NK cells.
G enetic immunotherapy with tumor antigen genemodified dendritic cells (DC) generates protective
antitumor responses mediated by antigen-specific CD4 þ T helper and CD8 þ cytotoxic T lymphocytes (CTL) in the majority of models tested (for a review see Ribas et al 1 ). Emerging evidence shows that DC vaccines are also very efficient at activating NK cells, and that these cells may collaborate in the activation of T-cell responses. Early murine studies showed that empty DC can stimulate NK cells leading to in vivo antitumor activity to NK preferred (MHC low) tumor cells. 2 The NK-DC interaction was shown to be contact-dependent and resulted in activation of both NK lytic activity and IFN-g production. 2 Subsequent studies have confirmed these observations in human in vitro cell cultures. [3] [4] [5] [6] [7] Additional studies focused on the possible role of NK cells in the activation of antigen-specific CTL responses generated by tumorantigen-loaded DC. Studies in both murine and human model systems showed that NK cells contributed to CTL generation. 8, 9 The contribution of NK cells to antitumor responses after tumor antigen gene-modified DC immunization has been less well-characterized. Early studies showed that this mode of immunization activated NK cells with a skewed inhibitory receptor repertoire, with decreased inhibitory receptors for MHC class I molecules expressed by the immunizing DC. 3 However, in this model, genetically modified DC generated antigen-specific CTL independent of NK cells. Multiple additional murine models confirmed that tumor antigen gene-modified DC directly stimulate CD8 þ CTL, usually requiring CD4 T help, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] which was shown to be mediated by CD40 crosslinking of the DC. 27 Two reports have shown that NK1.1 þ cells may be involved in the antitumor response generated by tumor antigen gene-modified DC. not only deplete ''classical'' NK cells, but also CD1-restricted NKT cells, Qa-1-restricted NK-CTLs or TCRrestricted CTL with constitutive or acquired NK1.1 expression. [30] [31] [32] [33] Given this controversy, we tested the possible contribution of NK cells in a well-established model of DCstimulated tumor antigen genetic immunotherapy. In this model, murine DC gene-modified to express MART-1 using a replication-incompetent adenoviral vector (Ad-VMART1/DC) protect syngeneic mice form a MART-1 positive B16 melanoma tumor challenge. This model has the following characteristics: AdVMART1/DC immunization in immunologically intact mice generates class I-restricted cytotoxic T-cell responses, 34, 35 with a predominantly Th1 phenotype, 27,34-36 not as a result of cross-presentation, 34 in which multiple, shortly spaced immunizations results in decreased protection due to fasL/fas-dependent activation-induced cell death. 37 Cotransduction of MART-engineered DC with adenoviral vectors expressing cytokine genes IL2 and IL7 did not enhance protection, while co-transduction with an IL12 adenoviral vector had an adverse impact on protection.
36
AdVMART1/DC immunization in a CD8-or CD4-deficient environment did not generate tumor-specific in vivo protection, CTL nor Th1 cytokine responses, while it generated very potent, and in fact superior levels of tumor immunity, when DC were matured by a CD40 crosslinking reagent, 27 supporting the requirement for a CD40-mediated interaction between DC, CD8 þ and CD4 þ T cells. However, this absolute requirement for CTL and helper cells still leaves the possibility of a contributing role of NK cells.
In the current studies we report that NK cells are indeed involved in the response to tumor antigen genemodified DC immunization, as depletion of NK cells abrogates protection. Mice genetically deficient of functional NK cells, but with intact CD8 þ and CD4 þ T-cell compartments, similarly have suboptimal protection, while reconstitution with NK cells is able to restore protection. In conclusion, tumor antigen gene-modified DC immunization stimulated antigen-specific CTL responses requiring a contribution of both CD4 þ T helper cells and NK cells.
Materials and methods

Cell lines and recombinant adenoviral vectors
B16, a murine melanoma, and EL4, a murine lymphoma cell line, were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained in vitro in DMEM (GIBCO) supplemented with 10% FCS (Gemini Products, Calabasas, CA, USA) and 1% (vol/ vol) penicillin, streptomycin, and amphotericin (Gemini). Generation of EL4(MART1) stable transfectants has been previously described. 34 Stably transfected cells were maintained in vitro under constant G418 selection (0.5 mg/ml, GIBCO). AdVMART1 and AdVLacZ are E1-deleted replication-deficient adenoviral vector based on human type 5 adenoviruses. The construction and characterization of these vectors has been described previously. 35, 38 The transgenes are driven by the human cytomegalovirus (CMV) early promoter/enhancer.
Preparation of DC and adenoviral transduction DC were differentiated from bone marrow progenitor cells derived from C57BL/6 mice (wild type or beige) by in vitro culture in GM-CSF and IL-4 as described by Inaba et al 39 with modifications. 38 DC were harvested as loosely adherent cells and transduced in RPMI with 2% FCS transduction media at a multiplicity of infection (MOI) of 100 viral plaque-forming units (pfu) per each DC when the final volume was 1 ml. Transduction was carried out for 2 h at 371C, after which time 5 volumes of 10% FCS RPMI media was added to neutralize free virus, and then the AdV-transduced DC were washed twice in PBS and resuspended in 0.2 ml of PBS per animal for injection.
Mice
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and beige mice (Lyst bg ) in a C57BL/6 background were purchased from Taconic Laboratory. Mice were bred and kept under specific pathogen-free conditions at the Animal Facility of the Division of Experimental Radiation Oncology, University of California Los Angeles (UCLA). Mice were handled in accordance with the UCLA animal care policy. Female or male mice (5-8 weeks old) were used, with each study using mice from only one gender and close birth dates.
Animal studies
Mice were immunized on days 1 and 8 with 1 Â 10 6 DC/ mouse administered subcutaneously in the right flank, and challenged on the left flank 10-14 days after the last immunization with B16 (8 Â 10 4 cells/animal). B16 cells used for tumor challenge were obtained from single-cell suspensions of progressively growing tumors in syngeneic mice to avoid the confounding effects of the presentation of media-and serum-derived epitopes. 34, 35, 38 Cell suspensions were washed extensively and injected into mice in a final volume of 0.2 ml of PBS/animal. Each treatment group typically contained five mice for in vivo tumor challenge studies, and one additional mouse per group to obtain splenocytes for in vitro studies (ELISPOT, 51 Cr release assays).
In vivo antibody treatment
In vivo monoclonal antibody ablation of NK1.1 þ (clone PK136) cells was performed by i.p. injection of 100 mg of purified endotoxin-free antibody/mouse/injection (Pharmingen) one day prior to immunization with Ad-VMART1-transduced DC. NK depletion was confirmed by NK cell activity microcytotoxicity assays using the NK-sensitive Yac-1 cell line as target cells (Yac-1 assay).
Adoptive transfer of DX5 þ cells NK cells were enriched by incubating splenocytes from unimmunized wild-type C57BL/6 mice with anti-NK (DX5) microbeads (Miltenyi Biotech, Auburn, CA, USA) before passing them through MACS high gradient LS separation columns (Miltenyi Biotech). NK cell enrichment was confirmed by flow cytometric analysis using NK1.1 and DX5 markers (BD Pharmingen). Cell suspensions were washed extensively and DX5 þ (NKenriched) splenocytes (5 Â 10 5 cells/animal) were injected intravenously in a volume on 0.1 ml of PBS one day prior to immunization with AdVMART1/DC.
Cytotoxicity assays
For in vitro microcytotoxicity assays, splenocytes were harvested 10-14 days after the last immunization, depleted of red blood cells by hypotonic lysis, cultured in vitro with or without irradiated EL4(MART-1) at a 25:1 ratio for 96 h in the presence of 10 U/ml of IL-2, and assayed in a standard 4-h chromium release test.
Cytokine profile by ELISPOT
Red blood cell-depleted splenocytes, cultured in vitro for 48 h at the same conditions described above for cytotoxicity assays, were added in duplicate three-fold dilutions to 96-well mixed cellulose plates (Multiscreen filtration system, Millipore, Bedford, MA, USA) precoated with anti-IFN-g antibody (Pharmingen, San Diego, CA, USA) and incubated for 24 h at 371C as previously described. 37 Spots were developed using a secondary biotin-labeled antibody and counted under a dissecting microscope.
Statistical analysis
Results of in vivo studies are presented as the mean and SEM of tumor volumes in each treatment group, or as the time to first tumor development. In tumor volume graphs, mice completely protected from a tumor challenge are presented separate from mice that did develop tumors to allow correct assessment of the rate of tumor growth. 38 Treatment groups divided into mice with and without tumors in a tumor volume plot are noted with the number of mice with (or without) tumor from that group over the total number of mice in the group, which is shown in parenthesis in the graph. Significance in tumor volume graphs is calculated using the t-test. Graphs of tumor development over time are presented using Kaplan-Meier plots, with the significance calculated using the Log-rank test. Prior studies suggested that wild-type C57BL/6 mice immunized with AdVMART1/DC induce complete or partial protection to a B16 MART-1-positive melanoma tumor challenge by CD8 þ CTL requiring CD4 þ T cell help mediated by CD40 modulation in the DC. 27 In the current studies, we tested the possible additional contribution of NK cells in this model system. Wild-type C57BL/6 mice were immunized with two weekly subcutaneous immunizations of AdVMART1 gene-modified DC. A subset of these mice were depleted of NK1.1 positive cells using PK136 hybridoma supernatant one day prior to immunization. Successful depletion of functional NK cells was confirmed by the absence of lytic cells against a YAC target in a chromium release assay (data not shown); NK depletion was monitored throughout the study period. Mice were challenged 10-14 days later with the MART-1 positive murine melanoma B16. Figure 1a shows a representative tumor protection experiment, with control C57BL/6 wild-type mice all developing rapidly progressing tumors. C57BL/6 mice immunized with DC transduced to express an irrelevant transgene (LacZ) demonstrated a slight delay in tumor outgrowth, but all succumbed to tumor challenge, supporting the antigen-specificity of this model, but also suggesting some degree of antigen-nonspecific response stimulated by DC. Wild-type C57BL/6 mice immunized with AdVMART1/DC had complete or partial protection to B16 tumor challenge, while those depleted of NK1.1 positive cells demonstrated a trend towards inferior protection (P ¼ 0.10, t-test). NK depletion partially abrogated the protective response in four replicate studies. Pooling the time to tumor development data from these studies confirmed a significant contribution of NK cells to the protective phenotype (Fig 1b, Po0 .0001, Log-rank test).
NK1.1 positive cells are required for in vitro immunological responses to tumor-antigen gene-modified dendritic cell vaccination
The effector role of NK cells can be mediated by cytokine production, lytic activity, or both. To better understand the role of NK1.1 positive cells in this model, we performed in vitro ELISPOT assays and microcytotoxicity studies using splenocytes from un-immunized mice, immunized mice, and mice depleted of NK1.1 positive cells prior to immunization. Consistent with previous findings, C57BL/6 wild-type mice immunized with Ad-VMART1/DC develop an increased frequency of antigenspecific IFN-g-producing splenic cells in vitro (Fig 2a) . Mice immunized with DC engineered to express an irrelevant transgene (AdVLacZ) demonstrate an increased background of interferon-gamma-producing cells above control, suggesting the stimulation of a significant number of nonantigen-specific IFN-g-producing cells. Mice depleted of NK1.1 positive cells exhibit a reduction in the frequency of IFNg-producing cells when compared with nondepleted AdVMART/DC-immunized mice, supporting a contribution of antigen-independent NK cells in the cytokine response generated by DC vaccines. Splenocytes from C57BL/6 wild-type mice immunized with AdVMART1/DC develop high lytic activity against a B16 target in microcytotoxicity assays, which was completely abrogated in splenocytes from NK-depleted mice, suggesting that NK1.1 positive cells are critical for the generation of lytic effectors in vivo. In this case, no background of antigen-nonspecific cytotoxicity was generated in mice immunized with AdVLacZ/DC. Thus, cells expressing the NK1.1 marker appear to make a critical contribution to MART-1-specific cytokine production and lytic activity in wild-type mice following immunization with AdVMART1-transduced DC.
Beige (NK-deficient) mice demonstrate inferior in vivo tumor protection to tumor antigen engineered dendritic cell vaccination compared to wild-type mice Depletion of NK1.1 positive cells using PK136 may deplete true NK cells, rare T cells that coexpress the NK1.1 marker, NKT and/or NK-CTL. [30] [31] [32] [33] To further study the contribution of NK cells in the response to AdVMART1/DC immunization we used beige mice in the C57BL/6 background, which have a severe functional deficiency in NK cells but have intact T and NKT cell compartments. 19 For these studies, beige mice were immunized with AdVMART-1-transduced DC derived from syngeneic beige mice to avoid the adoptive transfer of contaminating NK cells in DC vaccines. We first confirmed comparable expression of DC surface markers in beige DC by flow cytometry and comparable in vivo protection of beige and wild-type AdVMART1/DC in wild-type mice (data not shown). Beige mice immunized with AdVMART1/DC were not protected from a B16 tumor challenge (P ¼ 0.64), while similarly immunized wild type mice were protected (P ¼ 0.0004, Fig 3a) . Figure 3b shows the composite analysis of actuarial tumor development in four independent studies, confirming that beige mice immunized with AdVMART1/DC lacked protection to B16 tumor challenge. The inferior protection to a B16 challenge correlated with a decreased frequency of IFNg-producing cells in ELISPOT assays (Fig 4a) , and decreased lytic activity in microcytotoxicity assays (Fig 4b) . Taken together, these data suggest that the presence of functional NK cells is critical for protection following immunization with AdVMART1-transduced DC.
NK cells alone are not sufficient in generating in vivo tumor protection and in vitro responses to dendritic cell vaccination
To explore the possibility that NK cells alone could respond to gene-modified DC immunization, we compared the generation of protective immunity in NK- Figure 2 Antigen-specific IFN-g-producing cells and cytolytic splenocytes in AdVMART1/DC-immunized wild-type C57BL/6 mice is dependent on the presence of NK cells. Wild-type C57BL/6 mice were immunized with two weekly subcutaneous immunizations of AdVMART1 genemodified DC, with or without prior NK depletion using PK136 antibody. Splenocytes were harvested 2 weeks later, restimulated in vitro with EL4(MART1) and tested for IFN-g-producing cells in ELISPOT assays (a) and lytic activity to B16 in chromium release microcytotoxicity studies (b). competent but T and B cell-deficient SCID mice, 25, 26 and NK, T, and B cell-deficient SCID/beige mice. 27 Figure 5a shows a representative tumor protection experiment, with SCID and SCID/beige mice developing tumors regardless of immunization with melanoma-antigen-engineered DC. Immunization of SCID and SCID/beige mice with syngeneic DC gene-modified to express MART-1 failed to induce IFN-g-producing cells, while they were evident when immunizing wt C57BL/6 and T and NKT positive C57BL/6 beige mice (Fig 5b) . Taken together, these data suggest that NK cells alone are insufficient in generating responses to DC vaccination.
Adoptive transfer of NK cells improves in vivo tumor protection in beige mice
We then determined if the adoptive transfer of NK cells could restore the protective effects of immunization AdVMART1/DC in NK-deficient mice. Splenocytes from unimmunized wild-type C57BL/6 mice were harvested and cells expressing the NK marker DX5 were enriched using magnetic columns and injected intravenously one day prior to immunization with AdVMART1/DC. NK cell phenotype was confirmed by flow cytometric analysis and NK1.1 positive cells were enriched by nearly 10-fold (data not shown). NK cell adoptive transfer to beige mice restored the ability of these genetically NK deficient mice to reject a B16 tumor challenge following AdVMART1/ DC immunization (Fig 6, P ¼ 0.0002) . Similarly, adoptive transfer of DX5 þ splenocytes from wild-type mice to beige mice restored the presence of INF-g-producing cells at a level equivalent to wild-type mice, suggesting that NK cells collaborate in the response generated by DC in part by producing helper cytokines (Fig 7a) . The adoptive transfer of DX5 þ cells also completely restored the lytic activity to B16 in vitro (Fig 7b) . Therefore, adoptive transfer of NK cells to an NK-deficient environment restores their ability to generate MART-1-specific T-cell responses following AdVMART1/DC immunization.
Discussion
The current studies provide evidence that NK cells play a critical role in the immune response to vaccination with tumor antigen gene-modified DC. The role of CD4 Figure 4 Decreased numbers of IFN-g-producing cells and cytolytic splenocytes in congenitally NK-deficient mice immunized after AdVMART1/ DC immunization. Wild-type and beige mice were immunized with two weekly subcutaneous immunizations of AdVMART1 gene-modified DC. Splenocytes were harvested 2 weeks later, restimulated in vitro with EL4(MART1) and tested for IFN-g-producing cells in ELISPOT assays (a) and lytic activity to B16 in chromium release microcytotoxicity studies (b).
positive and CD8 positive cells in the immunological response to gene-modified DC has been well-characterized, 1 and our data suggest that protective antitumor immunity is also dependent on the presence of functional NK cells. Over the past several years, there have been increasing reports of the importance of NK cells in responses in immunotherapy. 2, 6, 7 Specifically, NK cells have been implicated as having important reciprocal interactions with DC, facilitating collaboration between innate and adaptive immune responses. 4, 5 In one carefully studied model of genetic immunization with adenovirally transduced DC that closely resembles our models, antitumor immunity was completely independent of CD8 þ T cells. 28, [40] [41] [42] When CD8 þ T cells were depleted using antibodies before or after immunization with AdVgp100-transduced DC, or when these DC were used to vaccinate CD8 genetically knockout mice, protection to a B16 tumor challenge was not impaired. On the contrary, absence of CD4 þ T cells completely abrogated the response, and absence of NK cells partially abrogated the response. In another model, NK cells were noted to be directly activated by adenovirally transduced DC. 29 This effect was noted to be related in part to the secretion of interleukin 12 . This group further investigated the contribution of NK cells to the immune response following DC vaccination in a tumor protection model, demonstrating 80% reduction in tumor protection in animals depleted of NK cells. 29 Our studies further support the notion that NK cells are involved in the generation of cytolytic and IFN-gproducing splenocytes following vaccination with melanoma-antigen-engineered DC, collectively leading to tumor protection. The study of NK cells is challenging, as there is no single NK cell marker and animal models of NK deficiency are not optimal. However, model systems using depletion of NK1.1 positive cells may aid in the study of NK cells, as this marker is predominantly expressed on NK and NK-T cells. 43 The NK1.1 antigen is also, however, expressed on rare populations of T cells and some cultured monocytes. 44 We therefore chose confirm the findings in studies with NK depleting antibodies in an NK-deficient animal model. Beige mice have a spontaneous mutation in the lysosomal trafficking regulator gene, Lyst 45 and have a severe deficiency in functional NK cells. 46 However, NK cells are still present in these mice, although they lack activity against NKsensitive targets, while NKT cells remain functionally active. 47 Several reports have addressed tumorgenicity in NK-deficient (beige) mice. Natural killer cells have been suggested to be important in the metastasis of murine tumors, as beige mice receiving intravenous injection of B16 melanoma developed a 10-fold increase in metastatic foci in the lung compared to wild-type C57BL/6 mice. 48 Studies using DC vaccination in NK-deficient (beige) mice have been quite limited. 28 Our findings of impaired protection to B16 tumor challenge in beige mice following immunization with MART-1-engineered DC further confirm the critical role of NK cells to the generation of an immune response following immunization with genemodified DC. Adoptive transfer of NK cells prior to immunization with melanoma-antigen-engineered DC significantly rescued protection to B16 challenge in beige mice. Therefore, ''classical'' NK cells, as opposed to other NK1.1 þ cellular subsets, are involved but not sufficient for the generation of protective responses to Ad-VMART1/DC immunization. This view is strengthened by our testing of the lack of protection by NK cells alone in SCID (T-cell deficient, but with functional NK cells) compared to SCID/beige mice (lacking both T and NK cells), supporting a requirement for a collaborative effort between T and NK cells in response to DC vaccination. We have previously extensively studied the antigenspecificity of AdVMART1/DC vaccination in this model. 27, 34, 37 Our prior data suggested that a clear MART-1-specific T-cell response could be defined in microcytotoxicity and ELISPOT assays using MART-1-transfected and nontransfected targets and restimulators, respectively. We did always note some background of antigen- nonspecific responses, mostly in the in vivo protection studies and in ELISPOT assays, but little in microcytotoxicity assays. In the current studies, we set up to clearly define this antigen-nonspecific response. The use of a high dose of DC to vaccinate mice (1 Â 10 6 cells) allowed for an enhancement of this effect, clearly noticeable in the ELISPOT assays presented in Figures 4a and 7a . We recognize that our data may be open to interpretations other than our view that NK cells collaborate with antigen-specific T cells activated by AdVMART1/DC to generate protective antitumor responses in vivo, lytic activity in microcytotoxicity assays and antigen-specific IFN-g-producing cells in ELISPOT assays. Antibody depletion of NK cells completely abrogated the lytic activity in microcytotoxicity assays (Fig 2b) , which may argue that most lytic activity in this assay is induced by NK effectors, with little role for MART-1-specific CD8 þ T cells. However, data in Figures 4b and 7b show that AdVMART1/DC vaccination can generate some lytic activity over background in beige mice, which increases by NK cell adoptive transfer. The residual lytic activity in beige mice may be due to their known NK leakiness, or that there is a true need for both NK cells and antigenspecific T cells to lyse B16 in vitro after AdVMART1/DC vaccination.
In conclusion, NK cells play a critical role in the immune response to vaccination with melanoma-antigenengineered DC. Our data suggest that generation of cytolytic T lymphocytes and in vivo protective responses are dependent on the presence of functional NK cells. Our Figure 7 Adoptive transfer of NK (DX5 þ ) cells restores cytokine and cytolytic response in beige (NK-deficient) mice following immunization with AdVMART1/DC. Wild type and beige mice, with or without additional adoptive transfer of DX5 þ NK cells from wild-type mice, were immunized with two weekly subcutaneous immunizations of AdVMART1 gene-modified DC. Splenocytes were harvested 2 weeks later, restimulated in vitro with EL4(MART1) and tested for IFN-g-producing cells in ELISPOT assays (a) and lytic activity to B16 in chromium release microcytotoxicity studies (b). data further suggests that NK cells alone are not sufficient in generating protective responses to DC vaccination, but that adoptive transfer of NK cells into an NK-deficient environment may restore the protective responses. Taken together, our data suggest that there is a critical interplay between NK cells and T lymphocytes following DC vaccination, resulting in the generation of antigen-specific CTL and cytokine production, and antitumor immunity. A better understanding of the signaling pathways of NK cell activation following DC vaccination and their crosstalk with antigen-specific CD4 þ and CD8 þ T cells may allow to augment responses to this DC-based immunotherapy.
